What laboratory monitoring is appropriate to detect adverse drug reactions in patients on cholesterol-lowering agents?
Metadata[+] Show full item record
Recommendations for measuring serum aminotransferase levels before initiating pharmacologic treatment for hypercholesterolemia, after 12 weeks of therapy, and periodically afterward are based on expert opinion. It is not recommended that serum creatine kinase (CK) levels be monitored for elevation indicative of myopathy during cholesterol-lowering therapy. (Grade of recommendation: D, based on expert opinion without explicit critical appraisal)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.